← All companies
$23.11
+1.63% (+$0.37) on the day
Close Nov 13, 2026
Market cap
$227M
1 month
−57.37%
52-week range
$17.40–$123.75
Last month
Why we cover it
Develops serotonin-targeting drugs related to psychedelics. Its lead program had positive Phase 2 data in epilepsy and is heading to Phase 3. Also listed in Canada on the CSE.
Financials
Recent financials aren't available in a standard format for this company. See its SEC filings ↗
In the Journal (3)
- Sep 29, 2026 Only 3 of 10 Psychedelic Companies Lobby Washington. One Just Joined — Twice, in the Same Quarter.
- Sep 23, 2026 Which Psychedelic-Company CEO's Pay Actually Matched Their Stock's Performance? We Checked All 10 — Almost None Did.
- Sep 11, 2026 The Psychedelic Money Rankings: $11 Billion Public, $1.6 Billion Private, $140 Million From Governments
Prices are end-of-day closes from Nasdaq; financials come from SEC filings. Not investment advice.